Replies to post #146275 on Biotech Values

[pcrutch]

PGNX likely needs to raise some cash IMO. No approval cost them a $40M milestone and now they need more clinical data. It also delays oral Relistor filing. I will wait for an offering.

[mcbio]

Any beneficiaries from PGNX's misfortune? IRWD's linaclotide has a pdufa for chronic constipation (not OIC) in september. I assumed NKTR would see a small jump but both NKTR and IRWD have gone down today.

THRX is another name that could benefit though I think the question still remains if the issues affecting Relistor are specific to the drug or do they extend to the other drugs targeting OIC as well?